Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Here's Why Merck (MRK) is a Strong Value Stock
12:04pm, Wednesday, 12'th Oct 2022
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merck partners with Moderna to develop a cancer vaccine
10:42am, Wednesday, 12'th Oct 2022
CNBC's Jim Cramer and the 'Squawk on the Street' team discuss Merck's decision to develop a cancer vaccine with mRNA developer Moderna.
Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients
10:07am, Wednesday, 12'th Oct 2022
Moderna's vaccine is being studied in combination with Merck's Keytruda to treat patients with high-risk melanoma, the deadliest form skin cancer.
3 Dividend Stocks in Warren Buffett's Secret Portfolio Most Likely to Soar in Q4
09:52am, Wednesday, 12'th Oct 2022 The Motley Fool
These stocks could add to Buffett's fortune by the end of 2022.
Moderna Surges As Merck Inks Deal To Co-Develop Personalized Cancer Vaccine Treatment
09:23am, Wednesday, 12'th Oct 2022
Merck opted Wednesday to help Moderna develop a personalized cancer vaccine based on messenger RNA technology, and MRNA stock rocketed. The post Moderna Surges As Merck Inks Deal To Co-Develop Persona
Merck, Moderna to develop personalized cancer vaccine
07:47am, Wednesday, 12'th Oct 2022
Merck & Co. Inc. MRK, +0.63% and Moderna Inc. MRNA, -2.19% said Wednesday that they plan to jointly develop and commercialize a personalized cancer vaccine. The investigational vaccine is currently be
3 Dividend Stocks in Warren Buffett's Secret Portfolio Most Likely to Soar in Q4
05:52am, Wednesday, 12'th Oct 2022
These stocks could add to Buffett's fortune by the end of 2022.
Merck (MRK) Gains As Market Dips: What You Should Know
09:45pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
In the latest trading session, Merck (MRK) closed at $91.05, marking a +0.63% move from the previous day.
With Meaningful Upside, This Cancer Stock Earns Analyst Upgrade
06:38pm, Tuesday, 11'th Oct 2022 Benzinga
BMO Capital Markets upgraded Seagen Inc (NASDAQ: SGEN) from Market Perform to Outperform with a price target of $178 from $177, saying the core business is undervalued.
BMO forecasts SGEN's commer
Merck (MRK) Posts Positive Results From PAH Drug Study
03:27pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.
Best Stocks To Buy Right Now? 3 Dow Jones Stocks To Watch
03:00pm, Tuesday, 11'th Oct 2022
3 Dow Jones Stocks to watch in the stock market in October 2022.
Merck (MRK) Posts Positive Results From PAH Drug Study
12:47pm, Tuesday, 11'th Oct 2022
Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.
Merck's Patent Cliff Doesn't Look So Frightening Anymore
12:33pm, Tuesday, 11'th Oct 2022
Merck could be sitting on a blockbuster from a recent acquisition that would help reduce dependence on cancer drug Keytruda.
Merck To Rally Over 29%? Here Are 5 Other Price Target Changes For Tuesday
11:45am, Tuesday, 11'th Oct 2022 Benzinga
Atlantic Equities raised Merck & Co., Inc. (NYSE: MRK) price target from $110 to $116. Atlantic Equities analyst Steve Chesney maintained an Overweight rating on the stock. Merck shares fell 0.8% to
Merck: Resilient To Macroeconomic Headwinds, Attractively Valued
08:05am, Tuesday, 11'th Oct 2022
Merck has demonstrated resilience in the current macroeconomic environment. MRK has a strong portfolio of drugs, and Keytruda keeps expanding its use cases.
